Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Opioid Overdose
- Opioid Use Disorder
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 19 years and 64 years
- Gender
- Both males and females
Description
Participants will receive a total of 6 subcutaneous monthly injections of extended-release buprenorphine, as well as medical management as per the local standard of care.
Participants will receive a total of 6 subcutaneous monthly injections of extended-release buprenorphine, as well as medical management as per the local standard of care.
Tracking Information
- NCT #
- NCT04815590
- Collaborators
- Indivior Inc.
- Investigators
- Principal Investigator: M. Eugenia Socias, MD, MSc. Assistant Professor, Department of Medicine, University of British Columbia
Get Well Soon